Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | BMC Microbiology

Fig. 6

From: SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry

Fig. 6

Effect of SJP-L-5 on the fate of the HIV-1 capsid in infected cells. a 293 T cells were infected with VSV-G pseudotyped HIV-1-GFP for 4 h in the presence of SJP-L-5 at a final concentration of 20 μg/ml, or DMSO as a negative control. At different time points post infection, the cells were collected and analyzed using the fate-of-capsid assay, as described in the Methods. The total input, soluble capsid, and pellet fractions were Western blotted using a monoclonal antibody directed against the HIV-1 p24 capsid protein. β-actin was used as pellet fraction control. b The quantification of the pelleted fraction relative to the input was calculated. Error bars indicate standard deviation in triplicate values. Statistical significance was analyzed by t test. *P < 0.05 and **P < 0.01 versus the no drug control. SJP: SJP-L-5

Back to article page